| 摘要 |
An antibody binding to human IL-1R and inhibiting the binding of human IL-1 to IL-1R, characterized in that said antibody is obtainable from hybridoma cell line MAK<h-IL-1RI>2D8 (DSM ACC 2601) or is a chimeric, humanized or T cell epitope depleted antibody variant or a fragment of said antibody showing an IC50 value of 35 pM or lower for the inhibition of IL-1 mediated secretion of Il-8 and IL-6 in human fibroblast cells like MRC5 (ATCC CCL 171) has advantageous properties for the treatment of inflammatory diseases. |
